Dasotraline (CAS 675126-05-3) – NDRI Antidepressant Pharmaceutical API

Dasotraline (CAS 675126-05-3) is a high-purity pharmaceutical API classified as a potent NDRI (Norepinephrine-Dopamine Reuptake Inhibitor), featuring a synthetic tricyclic molecular structure with dual-target affinity for norepinephrine and dopamine transporters. It selectively blocks the reuptake of these neurotransmitters in the central nervous system, increasing their synaptic concentrations to regulate mood, motivation, and cognitive function—without significant serotonergic activity that causes common antidepressant side effects. This premium API exhibits a long half-life (≈47 hours) and steady pharmacokinetics, ensuring sustained therapeutic effects with once-daily dosing potential.

It caters to the core needs of psychiatric drug manufacturers, pharmaceutical researchers, and clinical suppliers. Primarily developed for treating major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD), it aligns with the demand for well-tolerated, fast-acting mood-regulating therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, eliminating impurities that could impact clinical efficacy. For businesses prioritizing innovative, dual-mechanism psychiatric treatments, this Dasotraline API serves as a critical raw material for advancing antidepressant and neuropsychiatric medication development.